Madlyn Ferraro, RN, OCN, CCRC
UNC Cancer Network
Clinical Protocol Office
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
3rd Floor Administrative Tower, CB 7295
Chapel Hill, NC 27599-7295
Here is the link to the trial on clinicaltrials.gov
Also, please note that in January sanofi announced that INIPARIB in combination with Gemzar and Carboplatin did not meet its endpoints for first-line TNBC patients and first-line patients can no longer join the Expanded Access Protocol (EAP) but it is my understanding that if you had the EAP trial and it was not effective for you it does not exclude you from the INIPARIB–Ironotecan trial. Again, I am not a medical professional so please do not rely on anything I say. If your oncologist is interested he can contact the folks at UNC or at any of the other sites where the trial is being offered.
As an aside, I spoke again with Dr. Anders at the conference and I am so impressed by both her knowledge and her heart. There is, in my opinion, a patient-centered, caring culture at the Lineberger Cancer Center at UNC-Chapel Hill that is very profound. I have met Dr. Lisa Carey and Dr. Chuck Perou there. They are both deeply enmeshed in research regarding TNBC and also Dr. Carey is a medical oncologist, as is Dr. Anders. Again, they do not possess a magic wand but are working hard to unravel some of the mysteries.
On Sunday, I attended Dr. Cliff Hudis’ presentation on TNBC. He did an excellent job in explaining things to a lay audience and patiently answered our questions. One of the things that has been troubling many of us is that, in recent years, scientists have identified the fact that TNBC is not just one disease but has many subtypes. We have been wondering why in addition to testing for HER2neu, PR and ER further testing e.g. to see if the tumor was basal-like was not being done currently. Dr. Hudis explained that, in his opinion, we need clinical trials to prove that doctors can actually use this information to select more effective treatment options. For example, they would need better evidence that a certain chemotherapy will show some efficacy in treating a basal-like TNBC tumors, as opposed to other chemotherapy options. In other words the treatment will drive the use of pathologic testing rather than testing all tumors and then wondering how to use the information that results. Since the conference I have found e.g. several clinical trials examining basal-like tumors.
Here is one-
ABT-888 in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
|Sponsor:||University of Pittsburgh|
|Collaborator:||National Cancer Institute (NCI)|
|Information provided by:||National Cancer Institute (NCI)|
(the italics below are mine-)
- Establish the maximum tolerated dose, dose-limiting toxicities, and recommended phase II dose of chronically dosed, single-agent ABT-888 in patients with refractory BRCA1/2-mutated malignant solid tumor; platinum-refractory ovarian, fallopian tube, or primary peritoneal cancer; or basal-like breast cancer.
It was a bit frustrating that there were so many concurrent sessions but the podcasts will be helpful. That is the nature of most conferences and the next one I will attend ASCO in Chicago will be even more difficult to navigate.
Saturday, April 30, 2011
9:00 a.m. – 10:00 a.m. Registration and Continental Breakfast
10:00 a.m. – 10:15 a.m. Welcome and Introductions (LBBC)
10:15 a.m. – 10:45 a.m. Plenary Session I
Treating Metastatic Breast Cancer
Ruth Oratz, MD, FACP
10:45 a.m. – 11:15 a.m. Plenary Session II
In the Pipeline: Understanding Drug Approval
Dr. Robert Somer, MD
11:15 p.m. – 12:00 p.m. Questions & Answers with Drs. Oratz and Somer
12:00 p.m. – 1:30 p.m. Plated lunch, networking and visit with exhibitors
1:30 p.m. – 2:45 p.m. Workshop Session One (see below)
2:45 p.m. – 3:15 p.m. Break – Networking and visit with exhibitors
3:30 p.m. – 4:15 p.m. Plenary III
Support and Communication: Getting What You Need
Marilyn Brine Gilmour, MSW, LICSW
4:15 p.m. – 4:45 p.m. Questions and Answers with Ms. Gilmour
4:45 p.m. Closing remarks
5:00 p.m. – 6:00 p.m. Networking reception
Sunday, May 1, 2011
8:30 a.m. – 9:00 a.m. Continental Breakfast
9:15 a.m. – 10:30 a.m. Workshop Session Two (see below)
10:30 a.m. -11:00 a.m. Break
11:00 a.m. – 12:15 p.m. Closing Plenary Session (see below)
Ask the Expert: Managing It!
12:15 p.m. – 1:00 p.m. Closing Networking Reception
Workshop Session 1
Saturday, April 30
1:30 p.m. – 2:45 p.m.
Workshop A. Brain Mets
Carey K. Anders, MD, FRCPC
Workshop B. Eating Well for Feeling Good
Katrina Claghorn, MS, RD, CSO, LDN
Workshop C. Close-Up on Neuropathy
Steven C. Cohen, MD
Workshop D. Creating Your Stress Reduction Toolbox
Marilyn Brine Gilmour, MSW, LICSW
Workshop E. Taking Control: End-of-Life
Terri Altilio, LCSW, ACSW
Workshop F. Care for the Caregiver: Understanding Your Needs
Lara Krawchuk, MSW, LCWS, MPH
Workshop Session 2
Sunday, May 1
9:15 a.m. – 10:30 a.m.
Workshop G. Bone Mets
Adam Brufsky, MD
Workshop H. Acupuncture
Mary Ellen Scheckenbachm MAc, LOM
Workshop I. Close-Up on Fatigue
Ann M. Berger, PhD, APRN, AOCNS, FAAN
Workshop J. Flying Solo: Managing Mets as a Single Woman
Helen L. Coons, PhD, ABPP
Workshop K. Doctor-Patient Communication: Making Treatment Decisions
Rick Michaelson, MD
Workshop L. Triple-Negative Metastatic Breast Cancer
Clifford A. Hudis, MD
Ask the Expert Panel: Managing It!
Sunday, May 1
11:00 a.m. – 12:15 p.m.
- Helen L. Coons, PhD, ABPP
- Clifford A. Hudis, MD
- Spencer Rand, Esq.
- Mary Ellen Scheckenbach, MAc, LOM
- Woman Living with Metastatic Breast Cancer (TBD)